Data From CV Therapeutics Drug-Eluting Stent Program Presented at TCT Annual Scientific Symposium 2005
October 20 2005 - 5:10PM
PR Newswire (US)
PALO ALTO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that based on
preclinical data, its proprietary biopolymer stent coating
technology could potentially improve the performance of stents
coated with drugs such as paclitaxel or rapamycin. The data were
presented at the Transcatheter Cardiovascular Therapeutics (TCT)
Annual Scientific Symposium 2005 in Washington, DC. Stents are
small metal mesh devices which can be inserted into clogged blood
vessels to reopen them. Commercially available stents with drugs
such as paclitaxel or rapamycin in the coating have been shown to
reduce the frequency of restenosis, which is the reclosure of the
vessel after the stent has been implanted. CV Therapeutics and its
collaborators have developed a proprietary biopolymer designed to
control the drug release rate more precisely. The proprietary
manufacturing process used to create the biopolymer may limit or
reduce cracking and peeling following implantation of the stent.
"The data suggest that based on the controllable release rate and
biocompatibility, the CV Therapeutics biopolymer coating technology
could potentially improve state of the art drug-eluting stents,"
said Nicolas A. Chronos, M.D., chief medical and scientific officer
at the American Cardiovascular Research Institute. Preclinical
studies evaluated the drug release rates of commercially available
paclitaxel or rapamycin drug-eluting stents compared to the drug
release rates of stents coated with the CV Therapeutics biopolymer
and the respective drug. These studies showed that a drug-eluting
stent coated with the CV Therapeutics biopolymer controlled the
amount of drug released over the desired time with minimal cracking
or peeling of the coating. In addition, when comparing a
drug-eluting stent coated with the CV Therapeutics biopolymer to a
bare metal stent, these data showed similar inflammatory responses.
About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo
Alto, California, is a biopharmaceutical company focused on
applying molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics currently has three
programs in commercial or late-stage development: ACEON(R)
(perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and
regadenoson. CV Therapeutics also has other clinical and
preclinical drug development candidates and programs. The company
co-promotes ACEON(R), an ACE inhibitor, for the treatment of
essential hypertension and reduction of the risk of cardiovascular
mortality or non-fatal myocardial infarction in patients with
stable coronary artery disease. Ranexa is being developed as a
novel potential treatment for chronic angina. Regadenoson is being
developed for potential use as a pharmacologic stress agent in
myocardial perfusion imaging studies. Ranexa and regadenoson have
not been approved for marketing by any regulatory authorities.
Except for the historical information contained herein, the matters
set forth in this press release, including statements as to
development, clinical studies, regulatory review, and
commercialization of products, are forward- looking statements
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause
actual results to differ materially, including, early stage of
development; regulatory review and approval of our products; the
conduct and timing of clinical trials; the dependence on
collaborative and licensing agreements; commercialization of
products; market acceptance of products; and other risks detailed
from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2005.
CV Therapeutics disclaims any intent or obligation to update these
forward- looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: investors, Christopher Chai, Vice President, Treasury and
Investor Relations, +1-650-384-8560, or media, John Bluth, Senior
Director, Corporate Communications, +1-650-384-8850, both of CV
Therapeutics, Inc. Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Oct 2023 to Oct 2024